1

IROPICAN STUDY:

A Large Multicenter Case-Control Study to Evaluate Association of Opium Use and Risk of Lung, Bladder, Head and Neck and Colorectal Cancers

Hypothesis / Specific Aim

  • To assess sensitivity and specificity of the questionnaire in measurement of opium use in Iranian population;
  • To determine association between opium use and lung, colorectal, bladder, and head and neck cancers;
  • To determine the role of duration, and dose of opium use in cancer risk;
  • To assess geographic variation in association of cancer and opium use;
  • To determine the role of route of opium consumption (inhalation, oral use, etc.) on risk of cancer;
  • To determine the association between opium metabolites and risk of cancer;

To determine interaction of opium and other established risk factors of cancer including tobacco.

Target sample size 3200 Cases and 3200 Controls
Enrollment update 2563 cases and 2557 controls
Website last update date  20-Nov-2018

News

Rationale

  • Opium use and its side effects is an important health problem in Iran.
  • Several small studies found association between opium use and risk of cancer. However, there are some concerns on the validity of these findings and it is important to create valid reports about these associations.
  • Valid results about this issue will be used to communicate the results with policy makers for cancer prevention programs as well as with the general public for the public awareness programs.
  • We have set up a good national and international network to conduct well design study and answer an important public health questions.
  • In fact this is four projects and will answer this question about four common cancers which will be done as a package.
  • Three PhD students will use the data from this project for their thesis.
  • Our international collaborators have promised to use their capacity in their own country and rise further funding, in particular for molecular studies.
  • We also hope that we will use benefit from this network and provide an opportunity for our students to apply for international fellowship and experience research environment in the well-known universities in the world.
  • In addition to Opium use, we will analyses association of other risk factors like Hookah use, in which the epidemiological data is scarce.

BACKGROUND
Opium is a substance that extracted from the opium poppy. Derivatives of this substance have useful effect in medicine. For example, opioids drugs derived from this substance have an analgesic application reducing pain in chronic disease like cancer. Moreover, some opioids like codeine have an anti-cough effect [1, 2]. High prevalence of opium use was reported in the Near and Middle East/South-West Asia, primarily in Afghanistan and I.R of Iran [3]. Opium use is considered a criminal behavior and have stigma. In addition, there are laws against its use and distribution in I.R. of Iran. Despite this legislation, prevalence of opium use and other drugs has increased in European countries and was reported 8.7 per 1000 in 50 states of the USA and district of Colombian in 2002-2003 [4-6]. Prevalence of the opium use and its derivatives in Kerman province, which is located in the southern part of Iran, was 17.1% in 2005 [7]. Opium is used in different shapes including Teriak (crude opium), Shire (refined opium extract), and Sukhte (residual opium dross after smoking it) in different part of the Iran [8, 9]. Teriak and Shire can be ingested or smoked, while Sukhte is usually consumed orally [10].

Epidemiologic studies have reported significant associations between opium use and the risk of different cancers including: lung[10-12], bladder[13-19], oral cavity, larynx, pharynx [20, 21], stomach[22-24] and esophageal [22, 25, 26] cancers. In a recent systematic review, all studies about the association of opium use and cancer have been reviewed. This study reported that there is a significant association between opium use and risk of esophageal, stomach, larynx, and lung and bladder cancer. Interestingly, most of these studies were case-control and were published by Iranian researchers. Only two studies reported the cancer-opium association from other populations, one from Hong Kong [20] and one from Singapore [11]. Two cohort studies, one from northeast and one from northwest Iran, has so far reported an association between opium use and cancer risk. [27].
Two mechanisms have been suggested for carcinogenic effect of opium use, including the exposure to opium smoke and the alkaloid component of opium. First, opium users heat the opium to a high temperature and inhale the smoke through particular tube (pipe), when the opium contents starts to vaporize. The opium smoke contains polycyclic aromatic hydrocarbons which is a known carcinogen. In addition, the residual component in the pipe is called Sukhte and can be eaten without any changes or after refinement. Studies have shown that this residual substance have mutagenic role after metabolic activation in Salmonella Typhimurium [28]. This effect can also be caused by morphine and opium pyrolysates [29]. The main carcinogen component of Sukhte consist of all nitrogen containing heterocyclic components derived from pyrolysis of morphine[30]. In the second mechanism, opium contains alkaloid compounds that are absorbed in the body and lead to cancer.
Notwithstanding the several publication on association between opium use and cancer risk, they are usually performed in a small region and could not control for confounding variables properly, In addition, because of small power they could not investigate dose- response relationship, role of starting time of opium use, type and methods of consumption on the risk of cancer. Because opium use is not socially acceptable in Iranian population, the results of epidemiological studies is subject to the selection or measurement bias. However, most of the previous studies did not report response rates and sensitivity and specificity of their questionnaire for assessment of the opium use. Furthermore, available opium products have some additives such as lead, selenium, acetic anhydride, dried blood of animals and addicted persons. Type and amount of additives may vary from region to region. Therefore it is important to consider the role of opium additives in the cancer risk and compare the opium-cancer association between different regions.

REFERENCES:

 

1٫ Adcock, J., Peripheral opioid receptors and the cough reflex. Respiratory medicine, 1991. 85: p. 43-46.
2٫ Zeppetella, G., Opioids for the management of breakthrough cancer pain in adults: a systematic review undertaken as part of an EPCRC opioid guidelines project. Palliative medicine, 2011. 25(5): p. 516-524.

[wpex more=”Read more Click Here…” less=”Read less”]
3٫ world drug report 2013 New York.
4٫ Hamunen, K., et al., What do different databases tell about the use of opioids in seven European countries in 2002? European Journal of Pain, 2008. 12(6): p. 705-715.
5٫ Ishoy, T., L. Haastrup, and G. Hay, Estimating the prevalence of problem opioid use in Copenhagen 1997–۱۹۹۸٫ Danish medical bulletin, 2004. 51: p. 114-116.
6٫ McAdam-Marx, C., et al., Costs of opioid abuse and misuse determined from a Medicaid database. Journal of Pain and Palliative Care Pharmacotherapy, 2010. 24(1): p. 5-18.
7٫ Ziaaddini, H., Ziaaddini, Mohammad Reza, The household survey of drug abuse in Kerman, Iran. Journal of Applied Sciences, 2005. 5(2): p. 380-382.
8٫ Kheirandish, P., et al., Prevalence and correlates of HIV infection among male injection drug users in detention in Tehran, Iran. JAIDS Journal of Acquired Immune Deficiency Syndromes, 2010. 53(2): p. 273-275.
9٫ Nasrollahzadeh, D., et al., Opium, tobacco, and alcohol use in relation to oesophageal squamous cell carcinoma in a high-risk area of Iran. British journal of cancer, 2008. 98(11): p. 1857-1863.
10٫ Masjedi, M.R., et al., Opium could be considered an independent risk factor for lung cancer: a case-control study. Respiration, 2012. 85(2): p. 112-118.
11٫ MacLennan, R.D.C., J Day, NE Law, CH Ng, YKm Shanmugaratnam, K, Risk factors for lung cancer in Singapore Chinese, a population with high female incidence rates. International Journal of Cancer, 1977. 20(6): p. 854-860.
12٫ Khademi, H., et al., Opium use and mortality in Golestan Cohort Study: prospective cohort study of 50 000 adults in Iran. BMJ: British Medical Journal, 2012. 344.
13٫ Aliasgari, M., et al., Is bladder cancer more common among opium addicts? Urology journal, 2009. 1(4): p. 253-255.
14٫ Behmard, S., et al., Positive association of opium addiction and cancer of the bladder. Results of urine cytology in 3,500 opium addicts. Acta cytologica, 1980. 25(2): p. 142-146.
15٫ Hosseini, S.Y., et al. Opium consumption and risk of bladder cancer: A case-control analysis. in Urologic Oncology: Seminars and Original Investigations. 2010. Elsevier.
16٫ Ketabchi, A., et al., Evaluation of Bladder Cancer in Opium Addicted Patients in the Kerman Province, Iran, from 1999 to 2003. Journal of Research in Medical Sciences, 2005. 10(6): p. 355-357.
17٫ Nourbakhsh, A. and M.M.Z. Hatmi, Opium use in transitional cell carcinoma of the urinary bladder. Acta Medica Iranica, 2006. 44(4).
18٫ Sadeghi, A., S. Behmard, and S.D. Vesselinovitch, Opium: a potential urinary bladder carcinogen in man. Cancer, 1979. 43(6): p. 2315-2321.
19٫ Shakhssalim, N., et al., Prominent bladder cancer risk factors in Iran. Asian Pac J Cancer Prev, 2010. 11(3): p. 601-6.
20٫ Khoo, R., Radiotherapy of carcinoma of the Larynx. Annals of the Academy of Medicine, Singapore, 1981. 10(3): p. 307-310.
21٫ Mousavi, M.R.A., et al., Opium and risk of laryngeal cancer. The Laryngoscope, 2003. 113(11): p. 1939-1943.
22٫ Malekzadeh, M.M., et al., Opium Use and Risk of Mortality from Digestive Diseases: A Prospective Cohort Study. The American journal of gastroenterology, 2013. 108(11): p. 1757-1765.
23٫ Shakeri, R., et al., Opium: an emerging risk factor for gastric adenocarcinoma. International Journal of Cancer, 2013. 133(2): p. 455-461.
24٫ Naghibzadeh, T.A., et al., Opium as a Risk Factor for Upper Gastrointestinal Cancers: A Population-based Case-Control Study in Iran. Archives of Iranian medicine, 2014. 17(1): p. 2-6.
25٫ Ghadirian, P., et al., Oesophageal cancer studies in the Caspian littoral of Iran: some residual results, including opium use as a risk factor. International journal of cancer, 1985. 35(5): p. 593-597.
26٫ Shakeri, R., et al., Is opium a real risk factor for esophageal cancer or just a methodological artifact? Hospital and neighborhood controls in case-control studies. PloS one, 2012. 7(3): p. e32711.
27٫ Kamangar, F., et al., Opium use: an emerging risk factor for cancer? The Lancet Oncology, 2014. 15(2): p. e69-e77.
28٫ Hewer, T., et al., Ingested mutagens from opium and tobacco pyrolysis products and cancer of the oesophagus. The Lancet, 1978. 312(8088): p. 494-496.
29٫ Perry, P., et al., Induction of SCE by opium pyrolysates in CHO cells and human peripheral blood lymphocytes. Carcinogenesis, 1983. 4(2): p. 227-230.
30٫ Friesen, M., et al., Characterization and identification of 6 mutagens in opium pyrolysates implicated in oesophagel cancer in Iran. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 1985. 150(1): p. 177-191.
[/wpex]

Study Design

  • Methods:
    We are conducting a large multicenter case-control study to investigate the association between opium use and risk of different type of cancer including lung, Head and Neck, Colorectal, Bladder.
    Permission to participate in the study was obtained from seven provinces located in different part of Iran (Tehran, Fars, Kerman, Golestan, Mashhad, Khorasan, Kermanshah and Mazandaran Provinces) .In overall, we will recruit 3200 cases and 3200 healthy controls matched for age, sex, and residential place 800 cases and 800 controls for each cancer type. Controls will be selected from healthy people who visit general hospital.
  • Phases/steps of the research:
    Study designed in different steps including validation study, pilot study, and main study. First and second steps completed and we are conducting the main study. The data from participants consecutively are collecting from 17 hospitals in seven provinces. We enrolled 1452 cases and 1321 controls up to 3 February 2018.
    In order to manage the quality of data we visit each center two times each year. In addition, based on quality control protocol for monitor the data collection accuracy and precision all data were assessed by consecutive manager in each province and also in main center.
  • Biological Measurements:
    We are collecting 12 ml venous blood for each patient and control. 6 ml will be kept in a Vacationer tube with EDTA anticoagulant for DNA extraction and 3 mm of it for RNA extraction, 3 ml in a Vacationer tube without anticoagulant. In addition to blood sample, we are collecting the saliva sample from head and neck cancer cases and controls to evaluate the HPV infection.
  • Data:
    – Completed questionnaire (about …. Variables, demographic and clinical) based on face to face interviews.- Photographs of the oral lesions.

Collaborative Centers

– Kerman Province
–  Bahonar Hospital
–  Afzalipoor Hospital
–  Jawad Alaemah Hospital
–  Shafa Hospital
– Fars Province
–  Namazi Hospital
–  Saadi Hospital
– Golestan Province –  Sayad Sh Hospital
–  5th Azar Hospital
–  Taleghani Hospital
–  Payambar Azam Hospital
– Tehran Province –  Imam Khomeini Hospital
–   Masih Daneshvari Hospital
– Mazandaran Province –  Imam Khomeini Hospital
– Mashhad Province –  Imam Reza Hospital
–  Hasheminejad Hospital
–  Omid Hospital
– Kermanshah Province –  Ayatollah Taleghani Hospital
–  Imam Khomeini Hospital
–  Imam Reza Hospital
– Hormozgan Province –  Omid Radiation & Chemotherapy Center
–  Shahid Mohammadi Hospital
–  Imam Reza Hospital
– Boushehr Province –  Khalije Fars Hospital
–  Social Security Hospital
– Sistan & Baluchestan Province –  Ali Ebne Abitaleb Hospital
–  Khatamolanbia Hospital

Investigators

 

دکتر کاظم زنده دل

Kazem Zendehdel 

MD, PhD Epidemiology

(Principal Investigator)

Reza Malekzadeh 

MD, Gastroentrology

(Co-Investigator)

Farin Kamangar 

MD, PhD Epidemiology

(Co-Investigator)

 Akbar Haghdoost

PhD Epidemiology

(Co-Investigator)

Paolo Boffetta

MD, MPH ,Oncology

(Co-Investigator)

Elisabete Weiderpass Vainio

MD, PhD Epidemiology

(Co-Investigator)

Abbas Rezaianzadeh

MD, PhD, Epidemiology

(Co-Investigator)

Abdolvahab  Moradi

PhD, Virology

(Co-Investigator)

Technical Consultants

Afarin Rahimi Movaghar

MD, Psychiatry

Reza Shirkoohi

MD, PhD, Genetics

Hossein Poustchi

MD, PhD Clinical Epidemiology

Hossein Daneshvar

PhD, Microbiology

Reza Ghiasvand

PhD Epidemiology

Sareh Eghtesad

MSc, Nutrition Science

Hamideh Rashidian

PhD Student, Epidemiology

Project Manager

 

Maryam Hadji

MSc, Epidemiology

Nutritionist

Monireh Sadat Seyed Salehi

Genitics

Elmira Ebrihimi

Biobank Manager

Vahideh Peighambari

Job Exposure Analyst

Bayan Hosseini

Collaborative Centers

Tehran Province

Focal Points

Kazem Zendehdel

MD, PhD, Epidemiology

Executive Managers

Elham Mohebi

DVM, MPH, PhD Student

Interviewer

Mina Khaki

Fars Province

Focal Points

Abbas Rezaianzadeh

MD, PhD, Epidemiology

Executive Managers

Maryam Marzban

PhD Student, Epidemiology

Interviewer

Mahin Shiri

Interviewer

Marziyeh Dehghani

Interviewer

Zeinab Malekzadeh

Golestan Province

Focal Points

Abdolvahab  Moradi

PhD, Virology

Executive Managers

Mahin Gholipour

MD, MPH, PhD Student, Molecular Medicine

Interviewer

Aysan Gharanjik

Kerman Province

Focal Points

Akbar Haghdoost

PhD, Epidemiology

Executive Managers

Ahmad Naghibzadeh Tahami

PhD Student, Epidemiology

Interviewer

Behnaz Karimpour

Interviewer

Behnaz Karimpour

Kermanshah Province

Focal Points

Dr Farid Najafi

MD, PhD, Epidemiology

Executive Managers

Roya Safari

Interviewer

Bahare Safari

Mazandaran Province

Focal Points

Dr Reza Alizadeh

MD, PhD in Biomedical Sciences

Interviewer

Fatemeh Jabbari

Interviewer

Fatemeh Jabbari

Khorasan Razavi (MASHAD) Province

Focal Points

Dr Soudabeh Shahid Sales

M.D. Specialist in Oncology

Executive Managers

Saide Ahmadi Simab

Bushehr Province

Maryam Marzban

PhD, Epidemiology

Narges Arabzadeh

Sistan & Baluchestan Province

Dr Alireza Ansari Moghadam

PhD, Epidemiology

Mahdieh Bakhshi

Mahbubeh Bakhshi

Hormozgan (BANDAR ABBAS) Province

Abdol Azim Nejatizadehi

Fellowship in clinical molecular genetics

Masumeh Mahmudi

Foruzan Nematzadeh

Researchers in the Study Centers

Organization Chart

 

Financial Support and Grant

It is hard to think about such a study in Iran without a large grant from government.
Fortunately after our application, NIMAD grant organization accepted to help us to reach our important objectives.

Timeline / Schedule

4 years_ Starting time, started in 2016

فهرست